1, CRO:R&D+ clinical outsourcing
CRO is the abbreviation of English Contract Research Organization, which translates into pharmaceutical R&D contract outsourcing service organization. Originated in the United States in the early 1980s, it is an academic or commercial scientific institution that provides specialized services in basic medicine and clinical medicine research and development for pharmaceutical enterprises, medical institutions, small and medium-sized medical device research and development enterprises and even various government funds through contracts.
The introduction of CRO into China was initially limited to clinical services, and later extended to the whole process of drug research and development, from the screening of chemical substances to the promotion of drugs after marketing, with a wide range of services, which can meet the different needs of drug research and development enterprises.
2.CDMO: production outsourcing plus
CDMO is the abbreviation of English contract development and manufacturing organization, and it is a contract customization outsourcing service provider. On the basis of CMO, we also provide customized processing services. Such as: high-tech value-added technology development and other services. CDMO enterprises can provide pharmaceutical enterprises with the technological process research and optimization, dosage form development and trial production services needed in the production of innovative drugs, and further provide customized production services from kilograms to tons on the basis of the above research and development services.
CDMO enterprises deeply combine their own high-tech value-added technological R&D capability with large-scale production capacity, and through the supply mode of clinical trial production and commercial production, they can deeply connect with the whole supply chain system of pharmaceutical enterprises' R&D, procurement and production, and replace simple capacity output with high value-added technology output, thus promoting the capital-intensive CMO industry to upgrade to technology-intensive and capital-intensive CDMO enterprises in an all-round way.
Future trend of CDMO industry;
The future prospects are very bright.
With the continuous growth of the global pharmaceutical market and the demand of more and more biotechnology and pharmaceutical companies for outsourcing contract manufacturing and development services, CDMO industry will continue to maintain steady growth. At the same time, CDMO will continue to strive to improve service quality to meet the changing needs of customers.
2.CDMO industry will continue to innovate.
These innovations will include more effective process development, more efficient manufacturing technology, faster time to market and more flexible production mode. One of the important trends is digital transformation. CDMO enterprises will use emerging technologies such as big data, cloud computing and artificial intelligence to improve production efficiency and quality control, thus providing higher-level services.
3. The development trend of personalized medicine.
CDMO enterprises will provide more customized services according to the specific needs of customers and the characteristics of drugs. This trend is particularly obvious in the field of cancer treatment, because cancer patients need personalized treatment according to their genes, tumor types and treatment history. Therefore, CDMO enterprises need to have the corresponding technology and professional knowledge to meet the growing personalized medical needs of customers.